MedTrace Logo

Effects of Dapagliflozin on Progression of Alport Syndrome

NCT06226896 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2024-09-05

No results posted yet for this study

Summary

Recently, a series of large clinical trials have confirmed the cardio-renal protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors. but few patients with hereditary nephritis were included in these studies. This study is to evaluate the effects of dapagliflozin on slowing kidney disease progression in patients with Alport syndrome.

Conditions

  • Alport Syndrome

Interventions

DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10mg daily plus RAS inhibitor

Sponsors & Collaborators

  • Nanjing University School of Medicine

    lead OTHER

Principal Investigators

  • Yu An, MD · National Clinical Research Center of Kidney Diseases

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-15
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06226896 on ClinicalTrials.gov